Alteogen will invest KRW 253.2 billion to construct a new in-house biopharmaceutical production facility. The facility's operation is expected to expand production capacity going forward.
Alteogen will invest KRW 253.2 billion to construct a new in-house biopharmaceutical production facility. The facility's operation is expected to expand production capacity going forward.
The investment has been reported to strengthen the production network, including domestic and overseas contract manufacturing organizations (CMOs).